Company / Cash per Share
Esperion Therapeutics, Inc. Cash per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$0.81
FY2025
5-year range
$0.77 / $7.71
FY2021-FY2025
Trend
+4.4%
vs FY2024
Sector context
#155 of 205
Health Care
What the data says
Esperion Therapeutics, Inc.'s cash per share of $0.81 is lower than 76% of companies in the Health Care sector (FY2025). Cash per Share returned to growth in FY2025 after 4 years of decline, reaching $0.81.
Based on SEC 10-K filings.
0.81 in FY2025 with a 5-year CAGR of -40.8%.
Remained stable around $0.81 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -24.5%
- 5-Year CAGR
- -40.8%
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 205This company $0.81 Sector average $72.93
▼
-98.9% below sector average
Key checks
Key Insights
- In FY2025, cash per share increased 4.4% year-over-year.
- Ranks #155 out of 205 companies in the Health Care sector.
- Peak cash per share was recorded in FY2020.
- Lowest cash per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.81 | +4.4% |
| FY2024 | $0.77 | -3.0% |
| FY2023 | $0.80 | -57.5% |
| FY2022 | $1.88 | -75.6% |
| FY2021 | $7.71 | -30.5% |
| FY2020 | $11.09 | +79.1% |
| FY2019 | $6.19 | +348.1% |
| FY2018 | $1.38 | -4.0% |
| FY2017 | $1.44 | -14.9% |
| FY2016 | $1.69 | -51.8% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026